BackJamjoom Pharmaceuticals Factory Company Overview

Jamjoom Pharmaceuticals Factory Company Receivables

Jamjoom Pharmaceuticals Factory Company's receivables is $980M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$978.99M
↑ 22.84% YoYΔ $182.03M vs prior year quarter

Peer trimmed avg / median

Loading

Jamjoom Pharmaceuticals Factory Company Receivables History

Loading

Jamjoom Pharmaceuticals Factory Company vs. peers: Receivables Comparison

Loading

Jamjoom Pharmaceuticals Factory Company Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Jamjoom Pharmaceuticals Factory Company (4015.SR) FAQ

As of the most recent data (June 2026), 4015.SR shows a receivables of $980M. That compares with $800M in the prior-year period — up 22.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4015.SR's receivables is now $980M (was $800M) — a 22.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Jamjoom Pharmaceuticals Factory Company is outperforming or lagging.

Tracking 4015.SR's receivables over time shows whether Jamjoom Pharmaceuticals Factory Company is scaling, shrinking, or reshaping that part of the business. The current reading is $980M That compares with $800M in the prior-year period — up 22.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Jamjoom Pharmaceuticals Factory Company's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $980M) with ownership activity and broader fundamentals.